655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations

被引:0
|
作者
Tommasi, Stefania
Fedele, Vita
Lacalamita, Rosanna
Bruno, Michele
Schittulli, Francesco
Ginzinger, David
Scott, Gery
Eppenberger-Castori, Serenella
Calistri, Daniele
Casadei, Silvia
Seymour, Ian
Longo, Salvatore
Giannelli, Gianluigi
Pilato, Brunella
Simone, Giovanni
Benz, Christopher C.
Paradiso, Angelo
机构
[1] Natl Canc Inst, Clin Expt Oncol Lab, I-70126 Bari, Italy
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Stiftung Tumorbank Basel, Basel, Switzerland
[4] Buck Inst Age Res, Novato, CA USA
[5] Inst Oncol Romagnolo Forli, Ravenna, Italy
[6] Univ Bari, Bari, Italy
关键词
single nucleotide polymorphism; ERBB2; breast cancer; familiarity; risk;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human ERBB2 presents several SNPs. One of these, Ile655Val, introduces a structural change in the transmembrane region of ERBB2 and has been the focus of debate over its potential role as a susceptibility marker for breast cancer risk. Another SNP, Ala1170Pro, introduces a structural change in the carboxyl-terminal regulatory domain of the protein, but its clinical and biological importance remains undefined. The aim of this study was to investigate the association of rare alleles of both SNPs and the risk of developing breast cancer, BRCA1 alterations and clinical-pathological features of Caucasian breast cancer patients with familial history of breast/ovarian cancer. The originality of the present paper is that it is the only specifically focusing on the relationship between ERBB2 SNPs and familiarity/BRCA1 characteristics. A consecutive series of 628 patients with first diagnosis of breast cancer and 169 healthy people had DNA analyzed for both SNPs. Genotypic or allelic frequencies of ERBB2 SNPs in breast cancer patients were similar than in controls. The variant allele 655Val was significantly associated with younger age (p = 0.009) particularly associated with patient family history of breast cancer (p = 0.02). The 655Val allele was also more commonly found in invasive, while the variant 1170Pro in estrogen receptor positive breast cancers. Furthermore, this last SNP seems to be strictly associated with the presence of BRCA1 polymorphisms. In conclusion, these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining.
引用
收藏
页码:241 / 248
页数:8
相关论文
共 50 条
  • [21] Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes
    Margaret Smith
    Susan Fawcett
    Emanouil Sigalas
    Richard Bell
    Sophie Devery
    Nikolina Andrieska
    Ingrid Winship
    Familial Cancer, 2008, 7 : 119 - 124
  • [22] Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Timothy R Rebbeck
    Susan M Domchek
    Breast Cancer Research, 10
  • [23] The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer
    You, Chao
    Xiao, Qin
    Zhu, Xinyi
    Sun, Yiqun
    Di, Genhong
    Liu, Guangyu
    Hou, Yifeng
    Chen, Canming
    Wu, Jiong
    Shao, Zhimin
    Gu, Yajia
    Hu, Zhen
    GLAND SURGERY, 2021, 10 (01) : 262 - 272
  • [24] Mutational analysis of BRCA1 and BRCA2 genes in women with familial breast cancer from different regions of Colombia
    Cortes, Carolina
    Lucia Rivera, Ana
    Trochez, David
    Solarte, Melissa
    Gomez, Daniela
    Cifuentes, Laura
    Barreto, Guillermo
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2019, 17 (1)
  • [25] Genetics of breast cancer: contribution of BRCA1/2 genes alterations to hereditary predisposition
    Brankovic-Magic, Mirjana
    Dobricic, Jelena
    Krivokuca, Ana
    VOJNOSANITETSKI PREGLED, 2012, 69 (08) : 700 - 706
  • [26] Parity and breast cancer risk among BRCA1 and BRCA2mutation carriers
    Antonis C Antoniou
    Andrew Shenton
    Eamonn R Maher
    Emma Watson
    Emma Woodward
    Fiona Lalloo
    Douglas F Easton
    D Gareth Evans
    Breast Cancer Research, 8
  • [27] Risk Management for BRCA1/BRCA2 Mutation Carriers Without and With Breast Cancer
    Mainor, C. B.
    Isaacs, C.
    CURRENT BREAST CANCER REPORTS, 2020, 12 (02) : 66 - 74
  • [28] Oral contraceptives and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Jane C. Figueiredo
    Robert W. Haile
    Jonine L. Bernstein
    Current Breast Cancer Reports, 2009, 1 (3) : 139 - 147
  • [29] Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Oden, Lovisa
    Akbari, Mohammad
    Zaman, Tasnim
    Singer, Christian F.
    Sun, Ping
    Narod, Steven A.
    Salmena, Leonardo
    Kotsopoulos, Joanne
    ONCOTARGET, 2016, 7 (52) : 86687 - 86694
  • [30] Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Jan Lubinski
    Henry T. Lynch
    Susan L. Neuhausen
    Parviz Ghadirian
    Claudine Isaacs
    Barbara Weber
    Charmaine Kim-Sing
    William D. Foulkes
    Ruth Gershoni-Baruch
    Peter Ainsworth
    Eitan Friedman
    Mary Daly
    Judy E. Garber
    Beth Karlan
    Olufunmilayo I. Olopade
    Nadine Tung
    Howard M. Saal
    Andrea Eisen
    Michael Osborne
    Hakan Olsson
    Dawna Gilchrist
    Ping Sun
    Steven A. Narod
    Cancer Causes & Control, 2005, 16 : 667 - 674